Literature DB >> 11059769

Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.

A Oloumi1, S H MacPhail, P J Johnston, J P Banáth, P L Olive.   

Abstract

The outer cells of Chinese hamster V79 spheroids are about 10 times more resistant than monolayers to DNA damage and cell killing by the topoisomerase (topo) II inhibitor etoposide. Although the amount and catalytic activity of topo IIalpha are identical for monolayers or the outer cells of spheroids, and the cell proliferation rate is the same, our previous results indicated that phosphorylation of topo IIalpha is at least 10 times higher in V79 monolayers than in spheroids. Because phosphorylation of topo IIalpha has been associated with nuclear translocation, we examined subcellular distribution of Topo IIalpha in monolayers, spheroids, and xenograft tumors using immunohistochemistry. Topo IIalpha was located predominantly in the nucleus of V79, human SiHa, and rat C6 monolayers but was found mainly in the cytoplasm of the proliferating outer cells of spheroids formed from these cell lines. Conversely, the outer cells of WiDr human colon carcinoma spheroids showed predominantly nuclear localization of topo IIalpha, and only WiDr cells showed no increase in resistance to etoposide when grown as spheroids. Cells sorted from xenografts resembled the spheroids in terms of sensitivity to etoposide and location of topo IIalpha. When the outer cells of V79 spheroids were returned to monolayer growth, the rate of redistribution of topo IIalpha to the nucleus occurred with similar kinetics as the increase in sensitivity to killing by etoposide. Removal and return of individual outer V79 spheroid cells to suspension culture resulted in the translocation of topo IIalpha to the nucleus for the first 24 h, accompanied by an increase in sensitivity to DNA damage by etoposide. Therefore, the cytoplasmic topo IIalpha distribution in outer spheroid cells and tumors appears to correlate not with morphological changes associated with growth in suspension but rather with the presence of neighboring, noncycling cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059769

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells.

Authors:  Xiaoming Shi; Shengchun Wu; Yongbin Yang; Lei Tang; Yüexin Wang; Junjie Dong; Bonan Lü; Guangwei Jiang; Wei Zhao
Journal:  Tumour Biol       Date:  2014-04-23

Review 2.  Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Authors:  Joel G Turner; Jana Dawson; Christopher L Cubitt; Rachid Baz; Daniel M Sullivan
Journal:  Semin Cancer Biol       Date:  2014-03-12       Impact factor: 15.707

Review 3.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

Review 4.  Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy.

Authors:  Geeta Mehta; Amy Y Hsiao; Marylou Ingram; Gary D Luker; Shuichi Takayama
Journal:  J Control Release       Date:  2012-05-18       Impact factor: 9.776

5.  Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway.

Authors:  B Tan; Y Li; Q Zhao; L Fan; Y Liu; D Wang; X Zhao
Journal:  Cancer Gene Ther       Date:  2014-11-28       Impact factor: 5.987

Review 6.  Mass spectrometry imaging of therapeutics from animal models to three-dimensional cell cultures.

Authors:  Xin Liu; Amanda B Hummon
Journal:  Anal Chem       Date:  2015-07-02       Impact factor: 6.986

7.  Increased nanoparticle penetration in collagenase-treated multicellular spheroids.

Authors:  Thomas T Goodman; Peggy L Olive; Suzie H Pun
Journal:  Int J Nanomedicine       Date:  2007

8.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

9.  Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity.

Authors:  Toshio Uesaka; Tadahisa Shono; Daisuke Kuga; Satoshi O Suzuki; Hiroaki Niiro; Kyoko Miyamoto; Kenichi Matsumoto; Masahiro Mizoguchi; Masaru Ohta; Toru Iwaki; Tomio Sasaki
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

10.  Differential sensitivity to short-chain ceramide analogues of human intestinal carcinoma cells grown in tumor spheroids versus monolayer culture.

Authors:  Erica L Lowthers; Cynthia L Richard; Jonathan Blay
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Sep-Oct       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.